Form 8.5 (EPT/NON-RI) - Dechra Pharmaceuticals PLC

RNS Number : 8600Z

Bank of America Merrill Lynch

16 January 2024

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS
(OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")

1.	KEY INFORMATION

(a)	Name of exempt principal trader:

BofA Securities Europe SA

(b)	Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree

DECHRA PHARMACEUTICALS PLC

(c)	Name of the party to the offer with which exempt principal trader is connected:

EQT (EQT X EUR SCSp and EQT X USD SCSp)

(d)	Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure

15/01/2024

(e)	In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A"

N/A

2.	POSITIONS OF THE EXEMPT PRINCIPAL TRADER

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)	Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short Positions

Number

(1)	Relevant securities owned and/or controlled:

402,544

0.353%

8,822

0.008%

(2)	Cash-settled derivatives:

339,809

0.298%

(3)	Stock-settled derivatives (including options) and agreements to purchase/sell:

0 %

TOTAL:

402,544

0.353%

348,631

0.306%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)	Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:	N/A
Details, including nature of the rights concerned and relevant percentages:	N/A

3.	DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)	Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
1p ordinary	Purchase	2	38.68 GBP	38.68 GBP
1p ordinary	Sale	1	38.68 GBP	38.68 GBP

(b)	Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)	Stock-settled derivative transactions (including options)

(i)	Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)

Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise Price per unit
N/A	N/A	N/A	N/A	N/A

(d)	Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

4.	OTHER INFORMATION

(a)	Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"

None

(b)	Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"

None

(c)	Attachments

Is a Supplemental Form 8 (Open Positions) attached?

Date of disclosure:	16/01/2024
Contact name:	Frank Lui
Telephone number:	+44207 996 6418

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information
Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FEOEAEFKFFELEFA

RNS Number : 8600Z

Bank of America Merrill Lynch

16 January 2024

FORM 8.5 (EPT/NON-RI)

1.	KEY INFORMATION

(a)	Name of exempt principal trader:

BofA Securities Europe SA

(b)	Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree

DECHRA PHARMACEUTICALS PLC

(c)	Name of the party to the offer with which exempt principal trader is connected:

EQT (EQT X EUR SCSp and EQT X USD SCSp)

(d)	Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure

15/01/2024

(e)	In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A"

N/A

2.	POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a)	Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short Positions

Number

(1)	Relevant securities owned and/or controlled:

402,544

0.353%

8,822

0.008%

(2)	Cash-settled derivatives:

339,809

0.298%

(3)	Stock-settled derivatives (including options) and agreements to purchase/sell:

0 %

TOTAL:

402,544

0.353%

348,631

0.306%

(b)	Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:	N/A
Details, including nature of the rights concerned and relevant percentages:	N/A

3.	DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)	Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
1p ordinary	Purchase	2	38.68 GBP	38.68 GBP
1p ordinary	Sale	1	38.68 GBP	38.68 GBP

(b)	Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)	Stock-settled derivative transactions (including options)

(i)	Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)

Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise Price per unit
N/A	N/A	N/A	N/A	N/A

(d)	Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

4.	OTHER INFORMATION

(a)	Indemnity and other dealing arrangements

None

(b)	Agreements, arrangements or understandings relating to options or derivatives

None

(c)	Attachments

Is a Supplemental Form 8 (Open Positions) attached?

Date of disclosure:	16/01/2024
Contact name:	Frank Lui
Telephone number:	+44207 996 6418

END

FEOEAEFKFFELEFA

Date	16 Jan 2024
Time	10:11:59
Category	Holding(s) in company
ID	8600Z

Date	16 Jan 2024
Time	10:11:59
Category	Holding(s) in company
ID	8600Z

t

Company Information

RNS Metadata

Form 8.5 (EPT/NON-RI) - Dechra Pharmaceuticals PLC

Company Information

RNS Metadata